Hilal Oğuz

961 total citations
44 papers, 780 citations indexed

About

Hilal Oğuz is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Hilal Oğuz has authored 44 papers receiving a total of 780 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Molecular Biology, 22 papers in Oncology and 14 papers in Cancer Research. Recurrent topics in Hilal Oğuz's work include Angiogenesis and VEGF in Cancer (7 papers), Protease and Inhibitor Mechanisms (6 papers) and Cell death mechanisms and regulation (5 papers). Hilal Oğuz is often cited by papers focused on Angiogenesis and VEGF in Cancer (7 papers), Protease and Inhibitor Mechanisms (6 papers) and Cell death mechanisms and regulation (5 papers). Hilal Oğuz collaborates with scholars based in Türkiye and Antigua and Barbuda. Hilal Oğuz's co-authors include Vildan Yasasever, Derya Duranyıldız, Hakan Çamlıca, Erkan Topuz, Faruk Taş, Duygu Derin, Neşe Güney, Faruk Taş, Ethem Nezih Oral and Nejat Dalay and has published in prestigious journals such as Journal of Clinical Oncology, International Journal of Molecular Sciences and Biomedicine & Pharmacotherapy.

In The Last Decade

Hilal Oğuz

43 papers receiving 769 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Hilal Oğuz Türkiye 17 346 341 170 160 99 44 780
Vildan Yasasever Türkiye 19 435 1.3× 458 1.3× 204 1.2× 195 1.2× 134 1.4× 53 957
Katherine Chen United States 13 426 1.2× 357 1.0× 251 1.5× 99 0.6× 100 1.0× 24 980
Shou‐Ching Shih United States 13 464 1.3× 167 0.5× 140 0.8× 218 1.4× 68 0.7× 14 849
Virginie Defamie Canada 11 328 0.9× 210 0.6× 109 0.6× 268 1.7× 68 0.7× 13 751
Hiroyuki Eda Japan 17 409 1.2× 347 1.0× 195 1.1× 185 1.2× 61 0.6× 37 994
Sandra Cauwenberghs Netherlands 15 390 1.1× 160 0.5× 194 1.1× 155 1.0× 110 1.1× 17 964
Ken Tawara United States 11 291 0.8× 353 1.0× 196 1.2× 154 1.0× 64 0.6× 16 739
Jędrzej Grzegrzółka Poland 18 466 1.3× 427 1.3× 140 0.8× 259 1.6× 169 1.7× 76 1.1k
Frédérique Deshayes France 19 545 1.6× 241 0.7× 329 1.9× 143 0.9× 108 1.1× 31 1.2k
Daniëlle Raats Netherlands 15 391 1.1× 325 1.0× 158 0.9× 154 1.0× 113 1.1× 28 818

Countries citing papers authored by Hilal Oğuz

Since Specialization
Citations

This map shows the geographic impact of Hilal Oğuz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hilal Oğuz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hilal Oğuz more than expected).

Fields of papers citing papers by Hilal Oğuz

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hilal Oğuz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hilal Oğuz. The network helps show where Hilal Oğuz may publish in the future.

Co-authorship network of co-authors of Hilal Oğuz

This figure shows the co-authorship network connecting the top 25 collaborators of Hilal Oğuz. A scholar is included among the top collaborators of Hilal Oğuz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hilal Oğuz. Hilal Oğuz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Karabulut, Senem, Hilal Oğuz, Didem Taştekin, et al.. (2024). Investigation of the potential of miRNA candidates as non-invasive biomarkers for the diagnosis and follow-up of colorectal cancer. Pathology - Research and Practice. 254. 155094–155094. 4 indexed citations
2.
İlhan, Burak, et al.. (2024). The Diagnostic Value of circFBXW7, circABCB10, and circ0103552 Levels in Breast Cancer. Current Issues in Molecular Biology. 46(12). 14381–14393. 1 indexed citations
3.
Duranyıldız, Derya, et al.. (2016). Circulating serum levels of angiopoietin-1 and angiopoietin-2 in nasopharynx and larynx carcinoma patients. Tumor Biology. 37(7). 8979–8983. 5 indexed citations
4.
Karanlık, Hasan, İlker Özgür, Hilal Oğuz, et al.. (2016). Effect of intraperitoneal cetuximab administration on colonic anastomosis and early postoperative adhesion formation in a rat model. Turkish Journal of Surgery. 32(3). 157–161. 3 indexed citations
5.
Iliaz, Raım, Ümit Akyüz, Murat Serilmez, et al.. (2016). Role of several cytokines and adhesion molecules in the diagnosis and prediction of survival of hepatocellular carcinoma. Arab Journal of Gastroenterology. 17(4). 164–167. 8 indexed citations
6.
Karabulut, Mehmet, Halil Alış, Çiğdem Usul Afşar, et al.. (2015). Serum neural precursor cell-expressed, developmentally down regulated 9 (NEDD9) level may have a prognostic role in patients with gastric cancer. Biomedicine & Pharmacotherapy. 73. 140–146. 8 indexed citations
7.
Bilgin, Elif, et al.. (2013). For Which Cancer Types can Neuron-Specific Enolase be Clinically Helpful in Turkish Patients?. Asian Pacific Journal of Cancer Prevention. 14(4). 2541–2544. 5 indexed citations
8.
Bilgin, Elif, et al.. (2012). Markers of Bone Metastases in Breast and Lung Cancers. Asian Pacific Journal of Cancer Prevention. 13(9). 4331–4334. 8 indexed citations
9.
Kuru, Oğuzhan, et al.. (2011). Determination of serum CRP, VEGF, Leptin, CK-MB, CA-15-3 and IL-6 levels for malignancy prediction in adnexal masses. Journal of the Turkish-German Gynecological Association. 12(4). 214–219. 6 indexed citations
10.
Çamlıca, Hakan, Derya Duranyıldız, Hilal Oğuz, Ethem Nezih Oral, & Vildan Yasasever. (2008). The Diagnostic Value of Macrophage Migration Inhibitory Factor (MIF) in Gastric Cancer. Pathology & Oncology Research. 14(1). 79–83. 16 indexed citations
11.
Taş, Faruk, Derya Duranyıldız, Hilal Oğuz, et al.. (2008). Circulating levels of vascular endothelial growth factor (VEGF), matrix metalloproteinase-3 (MMP-3), and BCL-2 in malignant melanoma. Medical Oncology. 25(4). 431–436. 39 indexed citations
12.
Taş, Faruk, Derya Duranyıldız, Hilal Oğuz, et al.. (2008). Effect of zoledronic acid on serum angiogenic factors in patients with bone metastases. Medical Oncology. 25(3). 346–349. 20 indexed citations
13.
Derin, Duygu, Hilal Oğuz, Neşe Güney, et al.. (2007). Serum IL-8 and IL-12 levels in breast cancer. Medical Oncology. 24(2). 163–168. 50 indexed citations
14.
Oğuz, Hilal, Hakan Çamlıca, Derya Duranyıldız, et al.. (2006). Matriks metalloproteinazlar ve akciğer kanseri. DergiPark (Istanbul University). 21(2). 53–56. 3 indexed citations
15.
Taş, Faruk, Derya Duranyıldız, Hilal Oğuz, et al.. (2006). Serum Vascular Endothelial Growth Factor (VEGF) and Bcl-2 Levels in Advanced Stage Non-Small Cell Lung Cancer. Cancer Investigation. 24(6). 576–580. 34 indexed citations
16.
Taş, Faruk, Derya Duranyıldız, Hilal Oğuz, et al.. (2006). Serum Vascular Endothelial Growth Factor (VEGF) and Interleukin-8 (IL-8) Levels in Small Cell Lung Cancer. Cancer Investigation. 24(5). 492–496. 48 indexed citations
17.
Taş, Faruk, Derya Duranyıldız, Hilal Oğuz, et al.. (2005). Apoptosis of Lymphocytes in Peripheral Blood of Patients with Melanoma. Medical Oncology. 22(2). 177–182. 2 indexed citations
18.
Taş, Faruk, Derya Duranyıldız, Hilal Oğuz, et al.. (2005). The Value of Serum Bcl-2 Levels in Advanced Lung Cancer Patients. Medical Oncology. 22(2). 139–144. 7 indexed citations
19.
20.
Taş, Faruk, Derya Duranyıldız, Andaç Argon, et al.. (2004). Serum bcl-2 and survivin levels in melanoma. Melanoma Research. 14(6). 543–546. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Vildan Yasasever Breakdown of academic impact, for papers by Katherine Chen Breakdown of academic impact, for papers by Shou‐Ching Shih Breakdown of academic impact, for papers by Virginie Defamie Breakdown of academic impact, for papers by Hiroyuki Eda Breakdown of academic impact, for papers by Sandra Cauwenberghs Breakdown of academic impact, for papers by Ken Tawara Breakdown of academic impact, for papers by Jędrzej Grzegrzółka Breakdown of academic impact, for papers by Frédérique Deshayes Breakdown of academic impact, for papers by Daniëlle Raats
Rankless by CCL
2026